Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease

Current Opinion in Allergy and Clinical Immunology

Volumn 2, Issue 1, 2002, Pages 61-67

  Grootendorst, Diana C ^a   Rabe, Klaus F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; CILOMILAST; CORTICOSTEROID; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; SALBUTAMOL; THEOPHYLLINE;

ALLERGIC RHINITIS; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SELECTIVITY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG FUNCTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0036208692     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200202000-00010     Document Type: Review

References (47)

1. Global initiative for asthma. Global strategy for asthma management and prevention
2. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary
3. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma
4. Effect of theophylline withdrawal on airway inflammation in asthma
5. Salmeterol plus theophylline combination therapy in the treatment of COPD
6. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
7. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response
8. Cyclic nucleotide phosphodiesterases
9. The beta-adrenoceptor
10. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors
11. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
12. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A
13. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
14. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast
15. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor
16. Pharmacological characterization of Z15370A, a novel selective phosphodiesterase 4 inhibitor
17. The selective PDE4-inhibitor Awd 12-281 inhibits LPS-induced neutrophilia in domestic pig lung, an animal model of COPD comparison with steroids
18. Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004
19. NIK-616, a new type of selective phosphodiesterase IV (PDE IV) inhibitor with reduced emetic activity
20. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor
21. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indoles: Discovery of potent, selective phosphodiesterase type 4 inhibitors
22. The new PDE4 inhibitor roflumilast does not influence cardio-vascular function
23. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers
24. The safety of cilomilast (Ariflo) co-administration with oral theophylline: Cardiovascular profile
25. No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol
26. Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide
27. Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor
28. Influence of food intake on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor
29. Theophylline pharmacokinetics and liver function indexes in chronic liver disease
30. Pharmacokinetic interactions between theophylline and other medication (Part I)
31. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis
32. SB207499 improves pulmonary function in patients with asthma receiving concomitant inhaled corticosteroids
33. Four-week treatment with the new PDE4 inhibitor roflumilast in patients with exercise-induced asthma: Safety, efficacy and inhibition of TNF-α ex vivo
34. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomized, dose-ranging study
35. Cilomilast (Ariflo), a potent, selective inhibitor of phosphodiesterase 4, improves lung function in COPD patients: Results of a 6 month trial
36. Cilomilast (Ariflo) improves health status in patients with COPD: Results of a 6-month trial
37. Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: Results of a 6-month trial
38. Cilomilast (Ariflo), a potent, selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: Results of a 6 month trial
39. Cilomilast reduces healthcare resource utilization of chronic obstructive pulmonary disease patients
40. First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without co-administration of salbutamol and/or ipratropium in COPD patients
41. + T-lymphocytes and macrophages in patients with chronic obstructive pulmonary disease (COPD): A double-blind placebo-controlled, parallel-group study of bronchial biopsies
42. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
43. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease
44. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
45. The economic burden of COPD
46. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization
47. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study